Cargando…
Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α
BACKGROUND: Between 2009 and 2012, there was a worldwide shortage of agalsidase-β for the treatment of Fabry disease. Therefore, alternative treatments were needed, including switching to a different enzyme-replacement therapy. PURPOSE: This is an ongoing observational study assessing the effects of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189383/ https://www.ncbi.nlm.nih.gov/pubmed/24651606 http://dx.doi.org/10.1038/gim.2014.28 |